Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 15 December 2016 | By Zachary Brennan
The US Food and Drug Administration (FDA) on Thursday issued a proposed rule that looks to add six bulk drug substances to a list of such substances that can be used in compounding and to remove four other bulk drug substances that FDA evaluated and should not be included in the list.
If the proposed rule is finalized, the six bulk drug substances proposed for inclusion will be the first to be included on what’s known as the 503A bulks list. FDA’s Pharmacy Compounding Advisory Committee (PCAC) discussed the proposed additions and exclusions to the list in 2015, and the committee has since met three times in 2016 to discuss the inclusion and exclusion of other drug substances on the list.
“Because of the amount of time that had passed between the publication of the 1999 proposed rule and the enactment of the [Drug Quality Security Act] DQSA, FDA felt it was necessary to begin again to develop the 503A Bulks List,” the agency said in Thursday’s Federal Register.
In addition to the new additions and exclusions, FDA also proposes via this new rule to use the following criteria when evaluating nominated substances for inclusion on the list:
FDA proposes to consider each criterion and balance them on a substance-by-substance basis, to decide whether a substance is appropriate for inclusion on the list.
The Federal Register notice announcing the proposed rule provides additional details about the kind of information proposed to be considered for each criterion and how FDA proposes to weigh the information.
Based on FDA’s evaluation, as well as consultation with the Pharmacy Compounding Advisory Committee, the agency is proposing to include six bulk drug substances on the list:
FDA is proposing that the following four substances not be included on the 503A list:
FDA also notes in the proposed rule that it generally does not intend to take regulatory action against a State-licensed pharmacy, Federal facility, or licensed physician for compounding a drug product using a bulk drug substance that is not the subject of an applicable USP or NF monograph or a component of an FDA-approved drug product, if the other conditions in section 503A and the Food Drug & Cosmetics Act (FD&C Act) are met, until the substance is addressed in a final rule.
However, the agency also notes that any claims that FDA has approved a compounded drug made with a bulk drug substance that appears on the 503A list will cause the drug to be misbranded.
Individuals and organizations may petition FDA to add or delete bulk drug substances at any time after the final rule is published. Comments on the proposal need to be made in 90 days.
List of Bulk Drug Substances that can be used to Compound Drug Products
Tags: drug compounding, 503A bulks list, bulk drug substances, APIs
Regulatory Focus newsletters
All the biggest regulatory news and happenings.